Login
- A -
Austria- B -
Belgium- D -
Denmark- F -
FinlandFrance
- G -
GermanyGreece
- I -
Ireland (Eire)Italy
- N -
NetherlandsNorway
- P -
Portugal- S -
SpainSweden
Switzerland
- U -
United Kingdom
Population (2005)
9m
GDP (PPP data - 2004)
$255.4bn
Health expenditure (2002)
Health expenditure as proportion of GDP (2002)
Size of pharmaceutical market
Percentage of health expenditure spent on pharmaceuticals (2002)
Pharmaceutical Expenditure per capita (PPP)
Pharmaceutical market growth rate
Local currency
Krona (SEK)
Summary: Sweden
The Swedish market is characterised by a state pharmacy monopoly – the National Corporation of Swedish Pharmacies (Apoteket). The retail sales monopoly for medicines has been challenged by the European Court of Justice on 31 May 2005 as it ruled the current arrangements were contrary to Community Law. A period of uncertainty over the future development of the market structure best describes the current state of affairs.
The Pharmaceutical Benefits Board began testing nearly 2,000 medicines for reimbursement status in 2003, and is expected to finish its ambitious task in 2008.
Summary of report content
- Summary
- How is the healthcare system structured?
- What size is the pharmaceutical market?
- Are pharmaceuticals taxed?
- How are drug prices set?
- How are prices changed?
- How are drugs reimbursed?
- Is there a payback arrangement?
- Are hospital sales controlled?
- Are OTC prices regulated?
- How are pharmaceutical costs controlled?
- How are generic drugs priced?
- What are wholesale/pharmacy margins?
- Is parallel trade influential?
- What to look out for
- Glossary
- Useful Contacts
Your Basket
Your basket is currently empty.
Search News
News
25/05/2005
ECJ rules against state pharmacy monopoly
01/01/2005
Authorities order industry to slash pharmaceutical promotion
Related Items